About Prescient Therapeutics
Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.
Prescient Therapeutics Receives Two US Patents Covering PTX-200
Prescient Therapeutics (ASX: PTX), is pleased to announce that it has received notices of allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering its PTX-200 candidate for the treatment of leukemia and breast cancer. Once granted, the patents are expected to be valid until at least 2025…
CAR-T is a cell therapy which works by genetically modifying a patient’s own T-cells by adding a new receptor (CAR) to recognise cancer antigens. CAR-T therapy has achieved stunning success in certain blood cancers. However, conventional CAR-T also faces considerable challenges that limit their broader use, including manufacturing, safety and adaptability. The OmniCAR platform seeks to overcome these challenges. OmniCAR is a modular, universal CAR platform using technology exclusively from CAR-T pioneer the University of Pennsylvania (UPenn), as well as Oxford University. It has the potential to dramatically enhance the safety and efficacy of any CAR-T therapy, enabling in-house development of next-generation CAR-T therapies, and by dramatically improving external CAR-T programs it will create opportunities for collaboration and business development in the CAR-T field.
PTX - 100
PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1), thereby disrupting the oncogenic Ras pathway. PTX-100 is currently in a novel basket Phase 1b study of cancers driven by Rho and Ras mutations.
PTX - 200
PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known Akt, which plays a key role in the development of many cancers, including leukemia; breast cancer and ovarian cancer.
Prescient Therapeutics has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and spanning a range of different cancers. We have licensed technologies from, and also collaborates with, world-leading cancer centres in the United States as well as Australia.
You can visit our dedicated Investor Centre by clicking below. Here you will find our share price, company news, all ASX announcements, along with other key company information. You can also subscribe for email updates and invitations to online company investor briefings, whereby you can hear from management directly.
The broker reports included on this page of the website have not been commissioned or endorsed by Prescient Therapeutics Limited (Prescient) or its officers and are provided for information purposes only. The information contained in these report is not produced by Prescient and is not intended to be investment or financial product advice given by Prescient. Prescient recommends recipients of the reports make their own assessment of Prescient before making any investment decision. Any inquiries with respect to the reports should be directed to the relevant issuer of the report.
3rd Jul 2020
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) and a non-exclusive licence to…